

DAFTAR PUSTAKA

- Abd-el-atty, M. A., HafezEA, , Shedid, NH, El Sherbiny, DAH(2017) ‘Glucocorticoids Induced End Organs Damage in Patients with Systemic Lupus Erythematosus’, The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1117-1125.
- Åkesson, K., Vergnaud, P., Delmas, P. D., & Obrant, K. J. (1995). Serum osteocalcin increases during fracture healing in elderly women with hip fracture. *Bone*, 16(4), 427–430. [https://doi.org/10.1016/8756-3282\(95\)90187-6](https://doi.org/10.1016/8756-3282(95)90187-6)
- Al-Daghri, N. M., Aziz, I., Yakout, S., Aljohani, N. J., Al-Saleh, Y., Amer, O. E., ... Al-Badr, F. B. M. (2017). Inflammation as a contributing factor among post menopausal Saudi women with osteoporosis. *Medicine (United States)*, 96(4). <https://doi.org/10.1097/MD.0000000000005780>
- Al-Kushi, A., Azzeh, F., Header, E., ElSawy, N., Hijazi, H., Jazar, A., ... Alarjah, M. (2018). Effect of Vitamin D and calcium supplementation in patients with systemic lupus erythematosus. *Saudi Journal of Medicine and Medical Sciences*, 6(3), 137. https://doi.org/10.4103/sjmms.sjmms_134_17
- Arslan, Ş., Çeliker, R., & Karabudak, R. (2010). Cumulative corticosteroid doses and osteoporosis in patients with multiple sclerosis. *Turkish Journal of Rheumatology*, 25(4), 191–195. <https://doi.org/10.5152/tjr.2010.27>
- Baker-LePain, J. C., Nakamura, M. C., Shepherd, J., & von Scheven, E. (2011). Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. *Rheumatology*, 50(3), 611–619. <https://doi.org/10.1093/rheumatology/keq307>
- Bogaczewicz, J., Karczmarewicz, E., Pludowski, P., Zabek, J., Kowalski, J., Lukaszewicz, J., & Wozniacka, A. (2015). Feasibility of measurement of bone turnover markers in female patients with systemic lupus erythematosus. *Revista Brasileira de Reumatologia (English Edition)*, 55(2), 133–139. <https://doi.org/10.1016/j.rbre.2014.10.004>
- Brennan-Speranza, T. C., Henneicke, H., Gasparini, S. J., Blankenstein, K. I., Heinevetter, U., Cogger, V. C., ... Seibel, M. J. (2012). Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. *Journal of Clinical Investigation*, 122(11), 4172–4189. <https://doi.org/10.1172/JCI63377>

Buckley, L., & Humphrey, M. B. (2018). Glucocorticoid-Induced Osteoporosis. *New England Journal of Medicine*, 379(26), 2547–2556. <https://doi.org/10.1056/NEJMcp1800214>

Bultink, I. E. M. (2018). Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus. *Calcified Tissue International*, 102(5), 575–591. <https://doi.org/10.1007/s00223-017-0322-z>

Cabrera, D., Wolber, F. M., Dittmer, K., Rogers, C., Ridler, A., Aberdein, D., Kruger, M. (2018). Glucocorticoids affect bone mineral density and bone remodelling in OVX sheep: A pilot study. *Bone Reports*, 9(November), 173–180. <https://doi.org/10.1016/j.bonr.2018.11.001>

Chen, S. M., Peng, Y. J., Wang, C. C., Su, S. L., Salter, D. M., & Lee, H. S. (2018). Dexamethasone down-regulates osteocalcin in bone cells through leptin pathway. *International Journal of Medical Sciences*, 15(5), 507–516. <https://doi.org/10.7150/ijms.21881>

Devogelaer J-P. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. *Rheum Dis Clin North Am*. 2006;32(4):733–57.

Diaz-Franco, M. C., Franco-Diaz de Leon, R., & Villafan-Bernal, J. R. (2019). Osteocalcin-GPRC6A: An update of its clinical and biological multi-organic interactions (Review). *Molecular Medicine Reports*, 19(1), 15–22. <https://doi.org/10.3892/mmr.2018.9627>

Donatti, T. L., Koch, V. H. K., Takayama, L., & Pereira, R. M. R. (2011). Effects of glucocorticoids on growth and bone mineralization. *Jornal de Pediatria*, 87(1), 4–12. <https://doi.org/10.2223/JPED.2052>

Elhefny, A.-A. M., Hamza, S. M. H., & El Sherbiny, D. A. H. (2017). Frequency of Low Bone Mineral Density and Osteoporosis in a Cohort of Egyptian Patients with Systemic Lupus Erythematosus. *The Egyptian Journal of Hospital Medicine*, 69(3), 2030–2035. <https://doi.org/10.12816/0041055>

Elhefny, A.-A. M., Hamza, S. M. H., & El Sherbiny, D. A. H. (2017). Frequency of Low Bone Mineral Density and Osteoporosis in a Cohort of Egyptian Patients with Systemic Lupus Erythematosus. *The Egyptian Journal of Hospital Medicine*, 69(3), 2030–2035. <https://doi.org/10.12816/0041055>

Frediani B, et al. 2004. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid

arthritis: a 12-month randomized prospective controlled study. *J Rheumatol*;31(6):1083–7.

Fernandez, C. Jayasingh P, Pandi S, Saliyappan N, Murugesan A (2018). *Association of bone mineral density (BMD), body mass index (BMI) and serum osteocalcin in South Indian post menopausal women*, Indian Journal of Medical Specialities Trust, pp. 2–5. doi: 10.1016/j.injms.2018.02.002.

Food, U. S. (2013). Collagen Crosslinks and Biochemical Markers of Bone Turnover, 2013, 1–9.

Guo, Q., Fan, P., Luo, J., Wu, S., Sun, H., He, L., & Zhou, B. (2017). Assessment of bone mineral density and bone metabolism in young male adults recently diagnosed with systemic lupus erythematosus in China. *Lupus*, 26 (3), 289 – 293. <https://doi.org/10.1177/0961203316664596>

Hendrijantini, N., Alie, R., Setiawati, R., Astuti, E. R., & Wardhana, M. P. (2016). The correlation of bone mineral density (BMD), body mass index (BMI) and osteocalcin in postmenopausal women. *Biology and Medicine*, 8(6), 6–10. <https://doi.org/10.4172/0974-8369.1000319>

Hu, K., & Adachi, J. D. (2019). Glucocorticoid induced osteoporosis. *Expert Review of Endocrinology and Metabolism*. <https://doi.org/10.1080/17446651.2019.1617131>

Indriyani, N., Tridjaja, B., Medise, B. E., & Kurniati, N. (2017). Bone mineral density among systemic lupus erythematosus patient age 5-18 years with glucocorticoid treatment in child and adolescent outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta. *Journal of Physics: Conference Series*, 884(1). <https://doi.org/10.1088/1742-6596/884/1/012078>

Indriyani, N., Tridjaja, B., Medise, B. E., & Kurniati, N. (2017). Bone mineral density among systemic lupus erythematosus patient age 5-18 years with glucocorticoid treatment in child and adolescent outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta. *Journal of Physics: Conference Series*, 884(1). <https://doi.org/10.1088/1742-6596/884/1/012078>

Jardinet, D. (2000). Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. *Rheumatology*, 39(4), 389–392. <https://doi.org/10.1093/rheumatology/39.4.389>

Jeon, Y. K., Kim, B. H., & Kim, I. J. (2016). The diagnosis of osteoporosis. *Journal of the Korean Medical Association*, 59(11). <https://doi.org/10.5124/jkma.2016.59.11.842>

Kim, S. M., Kim, K. M., Joo, N. S., Kim, K. N., & Lee, D. J. (2010). Correlation of Undercarboxylated Osteocalcin (ucOC) Concentration and Bone Density with Age in Healthy Korean Women. *Journal of Korean Medical Science*, 25(8), 1171–1175. <https://doi.org/10.3346/jkms.2010.25.8.1171>

Knapen, M. H. J., Nieuwenhuijzen Kruseman, A. C., Wouters, R. S. M. E., & Vermeer, C. (1998). Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause. *Calcified Tissue International*, 63(5), 375–379. <https://doi.org/10.1007/s002239900543>

Knapen, M. H. J., Nieuwenhuijzen Kruseman, A. C., Wouters, R. S. M. E., & Vermeer, C. (1998). Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause. *Calcified Tissue International*, 63(5), 375–379. <https://doi.org/10.1007/s002239900543>

Korczowska, I., Olewicz-Gawlik, A., Hrycaj, P., & Lacki, J. (2003). The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: The prevalence of its anti-inflammatory action upon bone resorption. *Yale Journal of Biology and Medicine*, 76(1–6), 45–54.

Lufkin, S. V. and T. (2013). Bridging the gap: understanding embryonic IVD. *Cellular and Developmental Biology*, 10(2), 54–56. <https://doi.org/10.1002/stem.68.Mesenchymal>

Moser, S. C., & van der Eerden, B. C. J. (2019). Osteocalcin — A versatile bone-derived hormone. *Frontiers in Endocrinology*, 10(JAN), 4–9. <https://doi.org/10.3389/fendo.2018.00794>

Park, S. G., Jeong, S. U., Lee, J. H., Ryu, S. H., Jeong, H. J., Sim, Y. J., ... Kim, G. C. (2018). The changes of CTX, DPD, osteocalcin, and bone mineral density during the postmenopausal period. *Annals of Rehabilitation Medicine*, 42(3), 441–448. <https://doi.org/10.5535/arm.2018.42.3.441>

Paulson, C. (2015). Association of Topical Corticosteroid Use and Bone Mineral Density in Patients with Atopic Dermatitis Association of Topical Corticosteroid Use and Bone Mineral Density in. *Pacific University Common Knowledge*.

Phang, K. F., Cho, J., Lee, W., & Mak, A. (2018). Glucocorticoid-induced osteoporosis in systemic lupus erythematosus. *Rheumatology Practice and Research*, 3, 205990211880251. <https://doi.org/10.1177/2059902118802510>

Phang, K. F., Cho, J., Lee, W., & Mak, A. (2018). Glucocorticoid-induced osteoporosis in systemic lupus erythematosus. *Rheumatology Practice and Research*, 3, 205990211880251. <https://doi.org/10.1177/2059902118802510>

Phuan-udom, R., Lektrakul, N., & Katchamart, W. (2018). The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis. *Clinical Rheumatology*, 37(10). <https://doi.org/10.1007/s10067-018-4218-8>

Ranges, N. (n.d.). BMD: Interpretation and Normal Ranges.

Rathore, B., Singh, M., Kumar, V., & Misra, A. (2016). Osteocalcin: an emerging biomarker for bone turnover. *International Journal of Research in Medical Sciences*, 4(9), 3670–3674. <https://doi.org/10.18203/2320-6012.ijrms20162899>

Riancho-Zarrabeitia, L., Cubería, M., García-Canale, S., Daroca, G., García-Unzueta, M., Hernández, J., ... Martínez-Taboada, V. (2017). AB0511 Vitamin d: potential role in antiphospholipid syndrome, 1229.4-1230. <https://doi.org/10.1136/annrheumdis-2017-eular.5129>

Sarinho, E. S. C., & Melo, V. M. P. P. (2017). Doença Óssea Induzida Pelos Glicocorticoides: Mecanismos E Importância Na Prática Pediátrica. *Revista Paulista de Pediatria*, 35(2), 207–215. <https://doi.org/10.1590/1984-0462;2017;35;2;00007>

Sarkissian, A., Sivaraman, V., Bout-Tabaku, S., Ardoin, S. P., Moore-Clingenpeel, M., Mruk, V., ... Bowden, S. A. (2019). Bone turnover markers in relation to vitamin D status and disease activity in adults with systemic lupus erythematosus. *Lupus*, 28(2), 156–162. <https://doi.org/10.1177/0961203318815593>

Shetty, S., Kapoor, N., Bondu, J., Thomas, N., & Paul, T. (2016). Bone turnover markers: Emerging tool in the management of osteoporosis. *Indian Journal of Endocrinology and Metabolism*. <https://doi.org/10.4103/2230-8210.192914>

Shevchuk SV, Denyschych LP (2015). The Levels of Osteocalcin and Pyridinoline in Patients with Systemic Lupus Erythematosus: The Relationship with Structural and Functional State of Bone Tissue and Course of The Disease. *Lik Sprava* 2015 Oct-Dec;(7-8):57-65.

Stein, H., Perren, S. M., & Mosheiff, R. (2004). New Insights into the Biology of Osteocalcin Meredith. *Orthopedics*, 27(9), 915–918. <https://doi.org/10.1016/j.bone.2015.05.046>.New

Sun, Y. N., Feng, X. Y., He, L., Zeng, L. X., Hao, Z. M., Lv, X. H., & Pu, D. (2015). Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus. *BioMed Research International*, 2015. <https://doi.org/10.1155/2015/510514>

Susanto, L. T. M. (2011). Serum osteocalcin and bone mineral density in postmenopausal women. *Universa Medicina*, 30(3), 155–161.

Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000). Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. *Rheumatology*, 39(12), 1383–1389. <https://doi.org/10.1093/rheumatology/39.12.1383>

Kalaiselvi VS, Prabhu K, Ramesh M, Venkatesan V (2013). The Association of Serum Osteocalcin with the Bone Mineral Density in Post Menopausal Women. *Journal of Clinical and Diagnostic Research*. 2013 May, Vol-7(5): 814-816.

Wroblewska, L., Kitada, T., Endo, K., Siciliano, V., Stillo, B., Saito, H., & Weiss, R. (2016). *HHS Public Access*, 33(8), 839–841. <https://doi.org/10.1038/nbt.3301>.Mammalian

Xia, J., Luo, R., Guo, S., Yang, Y., Ge, S., Xu, G., & Zeng, R. (2019). Prevalence and Risk Factors of Reduced Bone Mineral Density in Systemic Lupus Erythematosus Patients: A Meta-Analysis. *BioMed Research International*, 2019. <https://doi.org/10.1155/2019/3731648>

Zahran, E., Abd-El Aziz Kora, M., El-Hady, H., Ragheb, A., & Soliman, S. (2014). Study of bone mineral density in patients with systemic lupus erythematosus. *Menoufia Medical Journal*, 27(3), 556. <https://doi.org/10.4103/1110-2098.145512>